1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
Two regular hemodialysis patients were assessed before, during and after therapy for 8 1/2 months with 1alpha-hydroxycholecalciferol (1alphaOHD3). The first patient (F.S.), treated with 2 mug daily, improved considerably with complete resolution of histological osteomalacia (O.M.), reduction in osteitis fibrosa (O.F.) and healing of Looser zones. The second patient (T.Y.), who was treated at the same time with a combination of phenobarbitone and phenytoin, showed no improvement while taking 3 mug of 1alphaOHD3 daily. It is suggested that hepatic microsomal enzyme inducing drugs antagonize the action of 1alphaOHD3 by interfering with its subsequent hepatic 25-hydroxylation.
D000469:Alkaline Phosphatase / Q000097:blood; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D006996:Hypocalcemia / Q000209:etiology; D007085:Ilium / Q000187:drug effects / Q000473:pathology; D008134:Long-Term Care; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D011859:Radiography; D006435:Renal Dialysis
D000927:Anticonvulsants; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D000469:Alkaline Phosphatase